March 24, 2021
With the loss of exclusivity for its major atypical antipsychotic drug Latuda (lurasidone) looming in 2023, Sumitomo Dainippon Pharma hopes to offset the impact of its patent cliff with products from Sumitovant Biopharma, a wholly owned unit created under its...read more